Bayerisches Zentrum für Krebsforschung (BZKF)

Advancing CNS tumor diagnostics with expanded DNA methylation-based classification (2026) Sill M, Schrimpf D, Patel A, Sturm D, Jäger N, Sievers P, Schweizer L, et al. Journal article Breaking primary checkpoint inhibitor resistance with intermittent alkylating chemotherapy in patients with metastatic melanoma: results of a multicentre phase II trial. (2026) Haferkamp S, Schilling B, Berking C, Drexler K, Gesierich A, Tomsitz D, Erdmann M, et al. Journal article Gastroenteropancreatic neuroendocrine neoplasms in children and adults: a comparative review (2026) Kuhlen M, Claus R, Pavel ME, Kunstreich M, Begum N, Lapa C, Redlich A Journal article, Review article Primary cardiac sarcoma: insights from two decades of multimodal management at LMU Munich (2025) Burkhard-Meier A, Di Gioia D, Jurinovic V, Hoberger M, Güler SE, Völkl M, Corradini S, et al. Journal article Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma (2025) Winkelmann M, Raj SS, Jain MD, Iacoboni G, Müller F, Hansmann L, Corona M, et al. Journal article Primary and secondary metastatic dissemination: multiple routes to cancer-related death (2025) Sparrer D, Blazquez R, Keil F, Einhell S, Lüke F, Uderhardt S, Gerner C, et al. Journal article, Review article A self-supervised multimodal deep learning approach to differentiate post-radiotherapy progression from pseudoprogression in glioblastoma (2025) Gomaa A, Huang Y, Stephan P, Breininger K, Frey B, Dörfler A, Schnell O, et al. Journal article Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatment (2025) Pelzl R, Benintende G, Gsottberger F, Scholz JK, Rübner M, Yao H, Wendland K, et al. Journal article Assessing the catchment area of German comprehensive cancer centers by merging geographic healthcare data - an initiative of the ONCOnnect consortium (2025) Kerscher A, Metzler M, Kapitza J, Bernhardt L, Dedner K, Krebs M, Brandts CH Journal article First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms (2025) Thomas S, Wermke M, Vučinić V, Wagner-Drouet E, Mackensen A, Zeiser R, Bug G, et al. Journal article